Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00510068 · OUTCOME

Plasma Angiogenesis Marker: Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR2)

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors · Source last updated 2015-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
pg/mL
Interval / dispersion
Standard Deviation
Time frame
Baseline, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1

What was measured

This biomarker is related to angiogenesis pathway, was analyzed to determine the effects of everolimus on plasma antiangiogenic molecules.

Analysis population: The Full Analysis Set (FAS) consists of all patients who were randomized.

Groups in this outcome

Everolimus 10 mg/Day

Participants received 10 mg per day of everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).

Placebo

Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Everolimus 10 mg/Day207
Placebo203

Reported measurements

Baseline (n:197, 193)
Values in pg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Everolimus 10 mg/Day30061.308607.379Not reportedNot reportedNot reported
Placebo31299.619091.460Not reportedNot reportedNot reported
Cycle 2 Day 1 (n: 185, 183)
Values in pg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Everolimus 10 mg/Day22691.186793.409Not reportedNot reportedNot reported
Placebo30223.218447.992Not reportedNot reportedNot reported
Cycle 3 Day 1 (n: 185, 173)
Values in pg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Everolimus 10 mg/Day22021.236393.414Not reportedNot reportedNot reported
Placebo29264.678408.405Not reportedNot reportedNot reported
Cycle 4 Day 1 (n: 172, 158)
Values in pg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Everolimus 10 mg/Day21218.176249.977Not reportedNot reportedNot reported
Placebo28308.588477.049Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        8607.379
        value
        30061.30
      2. group Id
        OG001
        spread
        9091.460
        value
        31299.61
    title
    Baseline (n:197, 193)
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        6793.409
        value
        22691.18
      2. group Id
        OG001
        spread
        8447.992
        value
        30223.21
    title
    Cycle 2 Day 1 (n: 185, 183)
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        6393.414
        value
        22021.23
      2. group Id
        OG001
        spread
        8408.405
        value
        29264.67
    title
    Cycle 3 Day 1 (n: 185, 173)
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        6249.977
        value
        21218.17
      2. group Id
        OG001
        spread
        8477.049
        value
        28308.58
    title
    Cycle 4 Day 1 (n: 172, 158)
denoms
  1. counts
    1. group Id
      OG000
      value
      207
    2. group Id
      OG001
      value
      203
    units
    Participants
description
This biomarker is related to angiogenesis pathway, was analyzed to determine the effects of everolimus on plasma antiangiogenic molecules.
dispersion Type
Standard Deviation
groups
  1. description
    Participants received 10 mg per day of everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).
    id
    OG000
    title
    Everolimus 10 mg/Day
  2. description
    Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).
    id
    OG001
    title
    Placebo
param Type
MEAN
population Description
The Full Analysis Set (FAS) consists of all patients who were randomized.
reporting Status
POSTED
time Frame
Baseline, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1
title
Plasma Angiogenesis Marker: Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR2)
type
SECONDARY
unit Of Measure
pg/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice